Electromed Stock Price, News & Analysis

Electromed (NYSE: ELMD) will release its fiscal 2026 first quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 after market close. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Investors can join by phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or listen via a live webcast in the company’s Investor Relations site. Replays will be available by phone at (844) 512-2921 (Domestic) or (412) 317-6671 (International) using Access ID 10203773, and online in the Events & Presentations section of the Investor Relations site.

Electromed (NYSE American: ELMD) will participate in the LD Micro Main Event XIX conference in San Diego, October 19-21, 2025. CEO Jim Cunniff will present on Monday, October 20, 2025 at 10:00 AM PT.

Investors can watch a live webcast via the Electromed Investor Relations site under Events & Presentations; institutional investors can register for the conference and request one-on-one meetings through LD Micro representatives.

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $10.0 million share repurchase authorization approved by its Board of Directors on September 9, 2025. This follows the completion of their previous buyback program in Q4 fiscal 2025.

The company will execute the repurchases through various means including open market transactions, private negotiations, and block trades, with timing and volume based on market conditions. CEO Jim Cunniff highlighted that the decision stems from strong operational performance and robust cash reserves, demonstrating the company's commitment to enhancing long-term shareholder value.

[ "New $10.0 million share repurchase program authorized", "Strong operational performance reported by management", "Robust cash reserves available for buyback execution", "Successfully completed previous share repurchase program in Q4 2025" ]

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, reported exceptional financial results for Q4 and FY 2025. The company achieved record quarterly revenue of $17.4 million (up 17.3%) and record annual revenue of $64.0 million (up 17.0%). Q4 net income reached $2.2 million ($0.25 per share), while FY 2025 net income was $7.5 million ($0.85 per share).

The company's direct homecare business grew 14.8% in Q4 and 15.7% annually, supported by 62 field sales employees. Operating income surged 46.8% for the full year to $9.7 million. Electromed maintained a strong financial position with $15.3 million in cash, no debt, and completed a $10.0 million share repurchase during FY 2025. The company was also added to the Russell 2000® and 3000® indexes in June 2025.

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has scheduled its fiscal 2025 fourth quarter financial results announcement for August 26, 2025, after market close.

Management will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International). A webcast will be available through the company's Investor Relations website.

For those unable to attend live, a replay will be accessible by phone using Access ID 10201085, and through the company's website.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The conference will take place from August 12-14, 2025 in Boston, MA.

President and CEO Jim Cunniff, along with CFO Brad Nagel, will deliver a presentation on Tuesday, August 12 at 12:30 pm ET. Investors can access the live webcast through the company's Investor Relations website, and institutional investors have the opportunity to request one-on-one meetings through Canaccord Genuity.

Electromed Inc. (ELMD) announced that its President and CEO Jim Cunniff will be presenting at the upcoming Investor Summit Virtual event scheduled for June 10, 2025. The presentation will provide an opportunity for investors to learn more about the company's developments and strategic initiatives. The virtual format allows for broader accessibility and engagement with the investment community.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, will be added to both the Russell 2000® Index and the Russell 3000® Index effective June 27, 2025. The inclusion comes as part of FTSE Russell's 2025 annual reconstitution, based on preliminary additions announced May 23, 2025.

The Russell 3000 Index encompasses the largest 3,000 U.S. public companies by market cap, while the Russell 2000 Index is its small-cap subset. These indices serve as key benchmarks for institutional investors and index funds, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes.

Electromed (NYSE American: ELMD) reported strong Q3 FY 2025 financial results, marking its tenth consecutive quarter of year-over-year revenue and net income growth. Net revenue increased 13.1% to $15.7 million, with operating income rising 16.2% to $2.1 million. Net income grew to $1.9 million ($0.21 per diluted share), up from $1.5 million ($0.17 per diluted share) year-over-year. The company's direct homecare business saw a 14.8% increase to $14.1 million. Operating cash flow improved to $7.5 million for the nine months ended Q3 FY 2025. The board approved a $5M stock repurchase authorization. As of March 31, 2025, Electromed maintained a strong financial position with $15.2 million in cash, $23.4 million in accounts receivable, and no debt.